We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| AbbVie Inc | NYSE:ABBV | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -1.64 | -1.01% | 161.00 | 163.6923 | 161.14 | 162.73 | 5,178,877 | 01:00:00 |
From May 2019 to May 2024
By Michael Dabaie
AbbVie Inc. said Rinvoq, or upadacitinib, monotherapy met primary and secondary endpoints in the second Phase 3 study in moderate to severe atopic dermatitis.
The co-primary endpoints were at least a 75% improvement in the Eczema Area Severity Index from baseline and a validated Investigator's Global Assessment for Atopic Dermatitis score of 0/1--clear or almost clear--at week 16.
The Measure Up 2 study evaluates 15 mg and 30 mg doses of upadacitinib monotherapy versus placebo in adolescents and adults with moderate to severe atopic dermatitis.
Significantly more patients receiving either dose of upadacitinib monotherapy showed improvement in skin clearance and reduction in itch compared to placebo at week 16, the company said.
Shares were up 0.4% to $99.90 premarket.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
July 21, 2020 09:35 ET (13:35 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year AbbVie Chart |
1 Month AbbVie Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
